Submandibular gland

FDA Approves US WorldMeds' MYOBLOC® (rimabotulinumtoxinB) Injection for Chronic Sialorrhea

Retrieved on: 
Monday, August 26, 2019
Organ systems, Drugs, Medical specialties, Botulism, Botulinum toxin, Neurotoxins, Toxins, Spasmodic torticollis, Salivary gland, Parotid gland, Tooth decay, Submandibular gland

The most common adverse reactions reported in all studies for chronic sialorrhea were dry mouth, dental caries, and dysphagia.1,2

Key Points: 
  • The most common adverse reactions reported in all studies for chronic sialorrhea were dry mouth, dental caries, and dysphagia.1,2
    "We are committed to helping patients who struggle with confidence due to their sialorrhea.
  • MYOBLOC was first approved by the FDA in 2000 for the treatment of adults with cervical dystonia.
  • - injected into the salivary glands (parotid and submandibular glands) and used to treat chronic sialorrhea in adults.
  • The effects of MYOBLOC and all botulinum toxin products may spread from the area of injection to produce symptoms consistent with botulinum toxin effects.